小剂量膀胱内注射Calmette Guérin芽孢杆菌：为什么它可能无关紧要

IF 1 4区医学 Q4 ONCOLOGY

Bladder Cancer Pub Date : 2022-06-03 eCollection Date: 2022-01-01 DOI:10.3233/BLC-211648

Ashish M Kamat, Niyati Lobo, Seth P Lerner, Roger Li, Justin T Matulay, Joan Palou, J Alfred Witjes, Morgan Rouprêt, Angela B Smith, Sam S Chang, Neal D Shore, Gary D Steinberg, Colin P Dinney, Robert S Svatek, Donald L Lamm

{"title":"小剂量膀胱内注射Calmette Guérin芽孢杆菌：为什么它可能无关紧要","authors":"Ashish M Kamat, Niyati Lobo, Seth P Lerner, Roger Li, Justin T Matulay, Joan Palou, J Alfred Witjes, Morgan Rouprêt, Angela B Smith, Sam S Chang, Neal D Shore, Gary D Steinberg, Colin P Dinney, Robert S Svatek, Donald L Lamm","doi":"10.3233/BLC-211648","DOIUrl":null,"url":null,"abstract":"When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and duration has been the subject of several randomized trials and is especially pertinent in the context of a global BCG shortage. Despite this, there appears to be uncertainty as to whether BCG dose or duration may be compromised in the event of shortage. As such, we wish to summarize the available evidence as an aid to the practicing urologist.","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2022-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181808/pdf/","citationCount":"0","resultStr":"{\"title\":\"Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter.\",\"authors\":\"Ashish M Kamat, Niyati Lobo, Seth P Lerner, Roger Li, Justin T Matulay, Joan Palou, J Alfred Witjes, Morgan Rouprêt, Angela B Smith, Sam S Chang, Neal D Shore, Gary D Steinberg, Colin P Dinney, Robert S Svatek, Donald L Lamm\",\"doi\":\"10.3233/BLC-211648\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and duration has been the subject of several randomized trials and is especially pertinent in the context of a global BCG shortage. Despite this, there appears to be uncertainty as to whether BCG dose or duration may be compromised in the event of shortage. As such, we wish to summarize the available evidence as an aid to the practicing urologist.\",\"PeriodicalId\":54217,\"journal\":{\"name\":\"Bladder Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2022-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181808/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bladder Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3233/BLC-211648\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bladder Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/BLC-211648","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

当使用膀胱内卡介苗(BCG)治疗非肌肉浸润性膀胱癌(NMIBC)患者时，必须考虑两个问题:1)给多少剂量，2)多长时间?最佳剂量和持续时间的问题一直是几个随机试验的主题，在全球卡介苗短缺的背景下尤其相关。尽管如此，在卡介苗短缺的情况下，卡介苗的剂量或持续时间是否会受到影响似乎还不确定。因此，我们希望总结现有的证据，以帮助执业泌尿科医生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter.

When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and duration has been the subject of several randomized trials and is especially pertinent in the context of a global BCG shortage. Despite this, there appears to be uncertainty as to whether BCG dose or duration may be compromised in the event of shortage. As such, we wish to summarize the available evidence as an aid to the practicing urologist.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Bladder Cancer Medicine-Urology

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that expedites our fundamental understanding and improves treatment of tumors of the bladder and upper urinary tract.